Additionally, the combination of glucocorticoids with inhibitors of Bcl-2 or MCL-1 such as venetoclax and bortezomib, respectively, has been shown to be a promising and safe treatment for relapsed/refractory multiple myeloma [43]. Here, BCL2 is linked to plasma cell myeloma.